Bayer Wins FDA Fast-Track for Lynkuet as JPMorgan Flags Stretched Q3 Hopes
Article excerpt
Highlighted: the sentence this signal was extracted from
US regulators have agreed to expedite their review of one of Bayer's most closely watched pipeline candidates. The FDA accepted a supplemental application for Lynkuet, whose active ingredient is elinzanetant, and handed the filing Priority Review status - a designation that typically shortens the approval timeline well below the standard track. The submission covers the drug's use in treating moderate-to-severe vasomotor symptoms in women undergoing endocrine therapy for hormone receptor-positive breast cancer. For the Leverkusen-based group, the regulatory nod marks a milestone in widening Lynkuet's therapeutic reach, targeting patients who endure severe hot flushes and similar complaints as a consequence of their cancer treatment. While pushing its internal development programs forward, Bayer is simultaneously shedding older products. Fellow German pharma company Grünenthal has struck a deal to acquire the rights to the cancer drug Stivarga, in a transaction worth up to EUR 375 million. Completion hinges on customary conditions and antitrust clearances, with both sides expecting the deal to close around the end of 2026 or early 2027. The divestment slots into a broader reshaping of Bayer's pharmaceutical operations. On the manufacturing side, the company is planning long-term capacity expansions, including a production site in the US state of Ohio carrying an estimated...
Keep reading with a free account
The rest of this article, and every signal for Bayer, is in your free account.
